Authors
Latest:
Differentiating Between the Classes of Gastric CancerAdam Bass, MD, assistant professor of medicine, Dana-Farber Cancer Institute, discusses the differentiation between the classes of gastric cancer.
Latest:
Brufsky Recaps PALOMA-2 Study of Palbociclib in Black Patients with aBCAdam Brufsky, MD, PhD, FACP, discusses background and next steps of the phase 3 PALOMA-2 study which evaluated palbociclib plus letrozole in patients that identified as Black or Hispanic with advanced breast cancer.
Latest:
Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AMLAdam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo, in which the patient with acute myeloid leukemia harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib.
Latest:
Functional Genomics of Barrett's Esophagus and Esophageal AdenocarcinomaAdam J. Bass, MD, assistant professor, Department of Medicine, Harvard Medical School, assistant professor of medicine, Division of Cellular and Molecular Oncology, Dana-Farber Cancer Institute, discusses functional genomics of Barrett's esophagus and esophageal adenocarcinoma.
Latest:
Dr. Adam Kibel on Treating Bone Metastases in Prostate CancerKibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer.
Latest:
Exploring Active Surveillance in Younger Patients With Prostate CancerAdam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.
Latest:
Immunotherapy Versus Targeted Therapy for Advanced MelanomaAdil Daud, MD, compares the roles of immunotherapy versus dabrafenib plus trametinib targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.
Latest:
Evaluating the Role of Liquid Biopsy in Breast CancerAditya Bardia, MBBS, MPH, discusses the value of liquid biopsies in the treatment landscape of breast cancer. The real value of liquid biopsy in this space lies in providing oncologists with insight on what’s happening in tumor evolution.
Latest:
The Future of ER+/HER2- mBC TreatmentDr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.
Latest:
Curing Versus Managing CLLAdrian Wiestner, MD, PhD, senior investigator, National Institutes of Health, discusses curing or managing patients with chronic lymphocytic leukemia (CLL).
Latest:
Recent Advances in the Treatment Landscape of MelanomaAhmad Tarhini, MD, PhD, director of the Melanoma and Skin Cancer Program and Immune-Oncology Research at the Cleveland Clinic Taussig Cancer Institute, discusses 3 recent trials that are changing the adjuvant treatment landscape of melanoma. The treatments presented in these trials have less toxicities overall and less impact on the quality of life, according to Tarhini.
Latest:
Reviewing the Current Treatment Landscape for Patients With HCCAhmed Omar Kaseb, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma.
Latest:
Later-Line Management of Metastatic Triple Negative Breast CancerTriple-negative breast cancer — defined as tumors that lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 amplification— is a heterogenous disease and clinically represents a major unmet need in the field of oncology. TNBC is associated with aggressive tumor biology and higher risk of recurrence and visceral metastasis, including brain metastasis.
Latest:
Checkpoint Inhibitors Under Investigation in Upper GI and Gastric CancersAiwu Ruth He, MD, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal and gastric cancers and which patients are most likely to benefit from the anti–PD-1 agents.
Latest:
Challenge in Treating Patients With Multiple MyelomaAjai Chari, MD, discusses the biggest challenge in treating patients with multiple myeloma.
Latest:
The Future of Patient Care in RRMMDr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.
Latest:
Clinical Development of Cyclin-Dependent Kinase Inhibitors in Lung CancerThis manuscript focuses on the latest clinical developments of newer generation selective CDK inhibitors in lung cancer.
Latest:
Gene Removal May Pose Future Treatment in Advanced MelanomaDespite the availability of several new agents in the past 5 years for the treatment of melanoma, patients with advanced melanoma still suffer poor prognoses.
Latest:
Safety and Efficacy Results of Phase I/II SCOOP Trial in mCRCAkihito Kawazoe, MD, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin plus pembrolizumab for treatment of patients with metastatic colorectal cancer.
Latest:
Advice To Community Oncologists Treating Patients With CRCAl B. Benson III, MD, FACP, FASCO, professor of medicine at Northwestern University, shares advice to community oncologists treating patients with colorectal cancer. He emphasizes looking carefully at different patient characteristics before making treatment decisions.
Latest:
Liquid Biopsy Results Extend the Use of Tissue Samples in Lung CancerAlain Borczuk, MD, discusses the current role for liquid biopsies versus tissue biopsies in lung cancer and the challenges that need to be overcome in this space.
Latest:
Key Considerations When Selecting Frontline Therapy in mCRCAlan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses key considerations in the selection of frontline therapy in metastatic colorectal cancer.
Latest:
Follicular Lymphoma: Emerging TreatmentsAn oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.
